Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Short-term Debt · Q1 FY2026 · quarter ended Mar 2026
Short-term debt falls 13.7% from a year ago
Short-term debt stood at $126K at the end of Q1 FY2026, down 13.7% from a year earlier and up 53.7% from the prior quarter. Over 3 fiscal years it compounded at +21.3% a year.
Context
- Short-term debt amounted to 0.2% of total assets at the end of Q1 FY2026, down 0.3 pp from a year earlier.
- Short-term debt increased in 1 of the last 3 fiscal years.
What to watch
Whether short-term debt keeps falling in the next quarterly balance sheet after a -13.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2025
- 82K USD
- Year-over-year change
- -10.9%
- 4-year CAGR
- +29.7%
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 82K | -10.9% |
| FY2024 | 2024-12-31 | 92K | +411.1% |
| FY2023 | 2023-12-31 | 18K | -60.9% |
| FY2022 | 2022-12-31 | 46K | +58.6% |
| FY2021 | 2021-12-31 | 29K | — |
Short-term Debt vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so short-term debt is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -13.7% is the 2nd highest of 3, against a peer median of +361.3%.
- Short-term debt amounts to 0.2% of total assets for UNCY, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
CBUSCibus, Inc. | Mar 2026 | $2.96M USD | +785.6% | — | 0.9% |
HYFTMindWalk Holdings Corp. | Jan 2026 | CA$430.33K CAD | -63.1% | +0.7% | 1.9% |
| Mar 2026 | $384K USD | — | — | 0.4% | |
| Mar 2026 | $126K USD | -13.7% | +21.3% | 0.2% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | — | — | 0.0% | |
ACRVAcrivon Therapeutics, Inc. Common Stock | Mar 2026 | $0 USD | — | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Peer median (excluding UNCY) | — | +361.3% | +0.7% | 0.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.